About Adcentrx Therapeutics
Founded in 2021 and headquartered in San Diego, California, Adcentrx Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer and other life-threatening diseases. The company's work centres on its proprietary i-Conjugation platform, which addresses the principal engineering challenges of ADC design, including stable conjugation chemistry, cleavable linker technology, and controlled drug-antibody ratio (DAR 8), to maximise payload delivery to solid tumour cells while limiting systemic toxicity.
Clinical Pipeline
Adcentrx has advanced two candidates into Phase 1a/b clinical trials. ADRX-0706 is a Nectin-4 ADC currently in Phase 1b evaluation across a range of advanced solid tumours; the US FDA has granted it Fast Track Designation for locally advanced or metastatic squamous cell cervical cancer. ADRX-0405 is a STEAP1-targeting ADC in Phase 1a evaluation for metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer; it carries FDA Orphan Drug Designation for gastric cancer and is regarded as a potential first-in-class candidate for its target. Both programmes build on the i-Conjugation platform's aim to deliver best-in-class or first-in-class ADCs with differentiated clinical profiles.
Funding & Partnerships
Adcentrx has raised approximately $101 million across three financing rounds, including a Series A+ of $51 million led by Eight Roads Ventures and extended with participation from Quan Capital and Partners Investment. The company has entered a multi-target antibody discovery collaboration with AvantGen to source novel antibody candidates for its ADC pipeline. Further information is available at adcentrx.com.
